Innova Captab share price, P/E, ROE & financials

On 6 Nov 2026, Innova Captab was priced at ₹1,021.10, or 37.9× trailing earnings, against an industry P/E of 28.7×, and the shares are 25% below their 52-week high. Sales and net profit grew 20% and 28% a year over 3 years, with ROCE of 15% and ROE of 14%. Debt is 0.32× equity, and its dividend yield is 0.4%. It is a small-cap company with a market cap of ₹5,843 Cr, ranked 41st of 154 Drug Manufacturers (Specialty & Generic) companies by market cap; the shares rose 25% over the past year.

As of 6 Nov 2026Prices are delayed about 15 minutes; fundamentals are from the quarter ended Jun 2026.How we calculate this

past year

Open: ₹1,039.80
Day high: ₹1,040.00
Day low: ₹1,011.60
Prev. close: ₹1,036.60
Volume: 18.9K

Health check

3 good · 2 fair · 1 to check

ReturnsIn line
+25.4% over a year, better than 4 of 7 peers.
Price tagPricier
P/E 37.9 vs industry 28.7.
GrowthStrong
Sales +20.1%, profit +27.5% a year over 3 years.
ProfitabilityAverage
ROCE 15.3% vs peer median 17.9%.
Balance sheetSolid
Debt 0.32× equity, interest covered 12.3×, Piotroski 6 of 9.
Red flagsNone found
No warning signs in the headline numbers.

Compared with 7 industry peers. Computed from reported figures. Educational, not a recommendation.

Drug Manufacturers - Specialty & Generic

153 listed peers. Screen the industry

Small cap

₹5,843 Cr, #41 of 154 in its industry by size.

Market sensitivity

Measuring against the NIFTY 50…

Key metrics

Last 12 months to Jun 2026: sales ₹1,749 Cr · profit ₹154 Cr

Market cap: ₹5,843 Cr; Small cap
P/E: 37.9; Industry 28.7
Price to book: 5.36; Peers 4.99
Dividend yield: 0.39%
ROE: 13.7%; Peers 14.7%
ROCE: 15.3%; Peers 17.9%
Debt to equity: 0.32; Debt ₹344 Cr
EPS (TTM): ₹26.91; Face value ₹10
OPM (TTM): 14.8%; Net margin 8.8%
Sales growth: +33.9%; Latest quarter vs a year ago
Profit growth: +42.3%; Latest quarter vs a year ago
Price to sales: 3.34; EV/EBITDA 23.9

Strengths

Quarterly profit up 42.3% on a year ago.
Quarterly sales up 33.9% on a year ago.
Positive operating cash flow in each of the last 4 years.

No obvious red flags in the headline numbers.

Derived automatically from reported figures. Not a recommendation.

About Innova Captab

Innova Captab Limited, an integrated pharmaceutical company, engages in the research and development, manufacture, distribution, and marketing of drugs and pharmaceutical products in India and internationally. The company provides contract development and manufacturing organization services to Indian pharmaceutical companies. It is also offers various generic formulation products, including cephalosporins, proton pump inhibitor, anticholinergic and…

Headquarters: Panchkula
Sector: Healthcare
ISIN: INE0DUT01020
Website: innovacaptab.com

Price range

52 weeks

₹622.00₹1,353.50

Today

₹1,011.60₹1,040.00

Avg volume (3M): 1 L
1-year return: plus 25.4%
From 52-week high: minus 24.6%

Peers · Drug Manufacturers - Specialty & Generic

Compare with peers Screen the whole industry

Company
SUNPHARMASun Pharmaceutical Industries	1,860.00	plus 1.69%	4,46,276	40.7	4.99	17.9%	13.1%	28.2%	10.4%	10.6%	0.86%	plus 8.2%
DIVISLABDivi's Laboratories	10,320.50	plus 1.78%	2,73,977	93.6	16.35	19.0%	16.2%	34.9%	11.0%	12.1%	0.29%	plus 49.0%
TORNTPHARMTorrent Pharmaceuticals	4,750.00	plus 0.85%	1,80,675	80.2	9.83	9.1%	15.7%	33.7%	13.3%	20.2%	0.80%	plus 31.7%
LAURUSLABSLaurus Labs	2,340.00	minus 0.26%	1,26,433	94.4	20.86	19.5%	24.0%	30.4%	3.8%	4.0%	0.09%	plus 138.6%
ZYDUSLIFEZydus Lifesciences	1,197.90	plus 0.41%	1,19,491	28.6	4.29	19.0%	14.7%	26.2%	16.5%	37.0%	0.08%	plus 22.8%
DRREDDYDr. Reddy's Laboratories	1,373.00	plus 0.51%	1,14,462	40.9	2.96	14.2%	7.3%	15.9%	11.0%	−1.7%	0.58%	plus 13.8%
CIPLACipla	1,411.00	plus 0.49%	1,13,993	39.4	3.22	14.9%	8.3%	17.3%	7.2%	11.5%	0.92%	minus 6.6%
INNOVACAPInnova Captab	1,021.10	minus 1.50%	5,843	37.9	5.36	15.3%	13.7%	14.8%	20.1%	27.5%	0.39%	plus 25.4%
Median of 7 peers	–	0.51%	1,26,433	40.9	4.99	17.9%	14.7%	28.2%	11.0%	11.5%	0.58%	22.8%

Quarterly results

Consolidated, ₹ crore

SalesSelect a row below to chart it

Jun 25	Sep 25	Dec 25	Mar 26	Jun 26
352	380	450	448	471
299	329	381	383	398
52.1	51.9	69.4	65.1	73.1
14.8%	13.6%	15.4%	14.5%	15.5%
4.5	4.2	1.7	1.6	2
2.9	5.5	4	4.6	4.4
11	11.3	11.4	11.4	11.7
42.7	39.2	55.7	50.7	59
27.3%	24.4%	24.3%	24.8%	25.2%
31	29.7	42.1	38.1	44.1
5.42	5.18	7.37	6.65	7.71

Profit & loss

Yearly, ₹ crore

Sales CAGR 3Y: +20.1%
Profit CAGR 3Y: +27.5%
EPS CAGR 3Y: +27.5%
ROE: 13.7%

Net profitSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
925	1,077	1,234	1,604
–	+16.4%	+14.6%	+29.9%
809	919	1,044	1,372
116	157	190	232
12.6%	14.6%	15.4%	14.5%
3.7	11	9.8	15.6
18.9	21.2	2.2	16.7
11.1	16	24.8	45.2
1.8	−1.8	−2	2.1
91.8	130	171	188
26.0%	27.2%	25.0%	25.1%
68	94.3	128	141
–	+38.8%	+35.9%	+9.9%
11.87	18.66	22.41	24.63

Forecast

Your assumptions, not a prediction

Balance sheet

At each financial year end, ₹ crore

Total assetsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
48	57.2	57.2	57.2
229	774	902	1,034
237	245	338	344
191	245	283	403
704	1,321	1,580	1,837
187	700	838	851
21.5	360	25.9	28
0	0	0.1	36.9
7	84.1	65.3	44.5
489	177	651	877
704	1,321	1,580	1,837

Cash flow

Yearly, ₹ crore

Cash from operationsSelect a row below to chart it

Mar 2023	Mar 2024	Mar 2025	Mar 2026
67.1	146	63.8	117
−90.8	−499	−152	−107
27.1	361	91.5	−21.7
3.4	8.2	3.8	−12.3
−79	−287	−172	−68.4
−11.9	−141	−109	48.2
–	–	–	−11.4

Shareholding pattern

Source: NSE filings

NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 20.7% (Yahoo estimate).

Major shareholders

NSE filing

Filings & events

News

No recent news coverage found.

My notes

Private to you